Benjamin A Weinberg1, Joanne Xiu2, Michael R Lindberg1, Anthony F Shields3, Jimmy J Hwang4, Kelsey Poorman2, Mohamed E Salem4, Michael J Pishvaian1, Randall F Holcombe5, John L Marshall1, Michael A Morse6. 1. Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. 2. Caris Life Sciences, Phoenix, AZ, USA. 3. Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. 4. Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA. 5. University of Hawaii Cancer Center, Honolulu, HI, USA. 6. Division of Medical Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
Abstract
BACKGROUND: Biliary tract cancers (BTCs) are a heterogeneous group of aggressive, rare malignancies with limited standard chemotherapeutic options for advanced disease. Recent studies have demonstrated potential novel biliary cancer targets and a possible role for immunotherapy in the treatment of patients with this disease. Intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), and gallbladder carcinoma (GBC) are frequently grouped together in clinical trials despite differences in tumor biology. METHODS: To further investigate tumor biology differences, we profiled 1,502 BTCs using next-generation sequencing (NGS), immunohistochemistry, in situ hybridization, and RNA sequencing. RESULTS: IHCCs had higher rates of IDH1, BAP1, and PBRM1 mutations and FGFR2 fusions; EHCCs had higher rates of KRAS, CDKN2A, and BRCA1 mutations; and GBCs had higher rates of homologous recombination repair deficiency and Her2/neu overexpression and amplification. IHCCs and GBCs had higher rates of potential positive predictive biomarkers for immune checkpoint inhibition (PD-L1 expression, high microsatellite instability, and high tumor mutational burden) than EHCCs. CONCLUSIONS: These findings support clinical molecular profiling of BTCs to inform potential therapeutic selection and clinical trial design based on the primary tumor's site of origin within the biliary tree.
BACKGROUND: Biliary tract cancers (BTCs) are a heterogeneous group of aggressive, rare malignancies with limited standard chemotherapeutic options for advanced disease. Recent studies have demonstrated potential novel biliary cancer targets and a possible role for immunotherapy in the treatment of patients with this disease. Intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), and gallbladder carcinoma (GBC) are frequently grouped together in clinical trials despite differences in tumor biology. METHODS: To further investigate tumor biology differences, we profiled 1,502 BTCs using next-generation sequencing (NGS), immunohistochemistry, in situ hybridization, and RNA sequencing. RESULTS: IHCCs had higher rates of IDH1, BAP1, and PBRM1 mutations and FGFR2 fusions; EHCCs had higher rates of KRAS, CDKN2A, and BRCA1 mutations; and GBCs had higher rates of homologous recombination repair deficiency and Her2/neu overexpression and amplification. IHCCs and GBCs had higher rates of potential positive predictive biomarkers for immune checkpoint inhibition (PD-L1 expression, high microsatellite instability, and high tumor mutational burden) than EHCCs. CONCLUSIONS: These findings support clinical molecular profiling of BTCs to inform potential therapeutic selection and clinical trial design based on the primary tumor's site of origin within the biliary tree.
Authors: Se Hoon Park; Yeon Ho Park; Jeong Nam Lee; Soo-Mee Bang; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee Journal: Cancer Date: 2006-01-15 Impact factor: 6.860
Authors: Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater Journal: N Engl J Med Date: 2010-04-08 Impact factor: 91.245
Authors: Su Jin Lee; Yoon La Choi; Yeon Hee Park; Seung Tae Kim; Eun Yoon Cho; Jin Seok Ahn; Young-Hyuck Im Journal: Cancer Chemother Pharmacol Date: 2010-12-18 Impact factor: 3.333
Authors: M Miyamoto; H Ojima; M Iwasaki; H Shimizu; A Kokubu; N Hiraoka; T Kosuge; D Yoshikawa; T Kono; H Furukawa; T Shibata Journal: Br J Cancer Date: 2011-06-14 Impact factor: 7.640
Authors: Kabir Mody; Prerna Jain; Sherif M El-Refai; Nilofer S Azad; Daniel J Zabransky; Marina Baretti; Rachna T Shroff; R Katie Kelley; Anthony B El-Khouiery; Adam J Hockenberry; Denise Lau; Gregory B Lesinski; Mark Yarchoan Journal: JCO Precis Oncol Date: 2022-06
Authors: Alessandro Rizzo; Angela Dalia Ricci; Antonio Cusmai; Silvana Acquafredda; Giuseppe De Palma; Giovanni Brandi; Gennaro Palmiotti Journal: Curr Oncol Date: 2022-01-27 Impact factor: 3.677
Authors: Marisa E Schwab; Hanbing Song; Aras Mattis; Andrew Phelps; Lan T Vu; Franklin W Huang; Amar Nijagal Journal: J Pediatr Surg Date: 2020-03-24 Impact factor: 2.545